Researchers from Tempus partnered with the Roswell Park Comprehensive Cancer Center to study aberrations in patients with metastatic non-small cell lung cancer. 

FGFR fusions represent a potential mechanism of resistance to EGFR inhibitors. This study characterizes the prevalence of these alterations and the landscape of co-mutations that may be of high interest to drug developers targeting FGFR fusions.

This study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2023.